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A B S T R A C T
Senescence is a state of proliferative arrest which has been described as a protective mechanism against the
malignant transformation of cells. However, senescent cells have also been demonstrated to accumulate with age
and to contribute to a variety of age-related pathologies. These pathological effects have been attributed to the
acquisition of an enhanced secretory profile geared towards inflammatory molecules and tissue remodelling
agents – known as the senescence-associated secretory phenotype (SASP). Whilst the SASP has long been con-
sidered to be comprised predominantly of soluble mediators, growing evidence has recently emerged for the role
of extracellular vesicles (EVs) as key players within the secretome of senescent cells. This review is intended to
consolidate recent evidence for the roles of senescent cell-derived EVs to both the beneficial (Bright) and det-
rimental (Dark) effects of the SASP.
1. Introduction
1.1. Senescence and the senescence-associated secretory phenotype (SASP)
Senescence is a stable state of proliferative arrest which occurs in
cells exposed to a variety of damaging stressors including telomere
shortening, DNA-damaging agents, irradiation, hydrogen peroxide
(H2O2), tumour suppressor loss, autophagy impairment and oncogene-
expression (Sharpless and Sherr, 2015; Gorgoulis et al., 2019). Senes-
cence is widely considered to be a protective mechanism, which acts to
prevent the malignant transformation of cells by instigating a mostly
irreversible cell-cycle arrest in response to potentially oncogenic stimuli
(Munoz-Espin and Serrano, 2014). A key hallmark of senescence is the
acquisition of an enhanced secretory profile through which senescent
cells modulate their local microenvironment – the senescence-asso-
ciated secretory phenotype (SASP) (Coppe et al., 2008; Coppé et al.,
2010). One key physiological role of the SASP is the removal of se-
nescent cells, via immune recruitment, following senescence induction
(Xue et al., 2007; Kang et al., 2011; Munoz-Espin and Serrano, 2014;
Yun et al., 2015). Another, is the contribution of the SASP to optimal
wound healing following injury (Demaria et al., 2014; Baker et al.,
2016). However, whilst these physiological roles may be considered the
“bright” side of the SASP it has also been demonstrated to have “dark”
pathological effects during ageing (Coppé et al., 2010). Senescent cells
have been demonstrated to accumulate with age (possibly due to
immune impairment) and, through the SASP, are implicated in a variety
of age-related pathologies including osteoarthritis, atherosclerosis,
diabetes, kidney dysfunction, neurodegeneration and vision loss (Baker
et al., 2016; Childs et al., 2016; Baar et al., 2017; Ogrodnik et al., 2017;
Xu et al., 2018). A key pathogenesis which links these diseases is the
maintenance of a persistent state of chronic sterile inflammation
(known as inflammageing) to which the SASP has been proposed as a
major contributor (Franceschi and Campisi, 2014). Furthermore, de-
pending on the setting, the SASP has been demonstrated to be both pro-
and anti- tumorigenic (Bavik et al., 2006; Coppe et al., 2008; Coppé
et al., 2010; Acosta et al., 2013). These diverse roles are driven by
heterogeneity in the composition of the SASP, which occurs as a result
of both cell type and senescence trigger, giving the SASP an intensely
context dependent role (Gorgoulis et al., 2019). Furthermore, the SASP
has been demonstrated to be a dynamic phenotype, developing during
the course of senescence induction (Hoare et al., 2016). These changes
are driven by the transcription factors NF-κB and C/EBPβ, which have
been identified as key determinants of SASP composition (Acosta et al.,
2008; Kuilman et al., 2008; Rodier et al., 2009; Chien et al., 2011). To
date, the functions of the SASP have been predominantly attributed to
soluble proteins (Coppé et al., 2010). However, emerging evidence
suggests extracellular vesicles (EVs) may play a key role in the complex
and varied roles of the SASP (Takasugi, 2018).
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2. Biogenesis and sub-classes of extracellular vesicles (EVs)
Following their discovery in 1983, EVs were primarily thought to be
a route for the removal of harmful cellular waste (Pan and Johnstone,
1983; Rashed et al., 2017). However, increasingly, their role in cellular
communication is becoming appreciated, particularly since the dis-
covery that EVs can deliver functional RNA to recipient cells (Valadi
et al., 2007; Edgar et al., 2016). Generally defined as lipid bilayer
bound vesicles secreted by cells, EVs consist of a highly heterogeneous
population that differs in size, function and biogenesis. This hetero-
geneity is reflected in the varied nomenclature that has been used to
describe EV sub-types. However, efforts have recently been made to
reach consensus when defining EV populations (Lotvall et al., 2014;
Théry et al., 2018).
Exosomes represent the smallest and most widely investigated
subset of EVs and are defined by their size (50−150 nm) and en-
dosomal origin (Colombo et al., 2014; Edgar et al., 2016). The budding
of endosomal membranes leads to formation of multivesicular bodies
(MVBs) containing intraluminal vesicles (ILVs) (Fig. 1) (Gould and
Raposo, 2013). The endosomal sorting complex required for transport
(ESCRT) is key to this process, mediating the recruitment of cargos,
budding and eventual cleavage processes of the endosomal membrane
(van Niel et al., 2018). The ESCRT machinery is subdivided into four
domains which are utilised in a stepwise manner during MVB forma-
tion. Initially, ESCRT-0 and -I subunits, such as TSG101 (tumour sus-
ceptibility gene 101), and accessory proteins, such as ALIX (ALG-2-in-
teracting protein X) and syntenin, cluster transmembrane and
cytoplasmic cargos at microdomains on the MVB membrane. This is
followed by recruitment of ESCRT-II and -III and associated proteins
which perform membrane budding and scission to release intraluminal
vesicles (ILVs) (Colombo et al., 2013). Components involved in MVB
formation, such as TSG101 and ALIX, are considered markers of exo-
somal biogenesis (Tamai et al., 2010; Baietti et al., 2012).
An ESCRT-independent biogenesis pathway also exists, which may
utilise the clustering of cone shaped lipids to trigger spontaneous
membrane budding (Tkach and Théry, 2016). This alternative pathway
has been demonstrated to produce CD63 enriched ILVs following
ESCRT knockdown (Stuffers et al., 2009). CD63 is a tetraspanin which,
alongside CD9 and CD81, also features in exosome biogenesis, clus-
tering with other membrane proteins and contributing to the sorting of
exosomal cargoes (Buschow et al., 2009; Chairoungdua et al., 2010;
Charrin et al., 2014). ILV formation may also be driven through the
production of ceramide by neutral sphingomyelinase, which facilitates
the required endosomal membrane curvature (van Niel et al., 2018).
Importantly, this process may be perturbed through use of the inhibitor
GW4869, which has proven a useful experimental tool (Trajkovic et al.,
2008). Whilst the process of ILV biogenesis is complex and not yet fully
elucidated, ILV formation leads to classification of endosomes as MVBs.
MVBs have several possible fates, one of which is fusion with lysosomes
for enzymatic degradation and, indeed, in cells with impaired lyso-
somal function, exosome production has been demonstrated to increase
(Eitan et al., 2016; Schorey and Harding, 2016) — potentially acting as
an alternative mechanism through which to dispose of harmful or de-
fective proteins. For ILVs to be released from a cell, thus becoming
exosomes, the MVB must avoid trafficking to the lysosome in favour of
the plasma membrane. The cargo and composition of ILVs plays a key
role in their eventual trafficking fate, with the formation of a complex
between ALIX, syntenin and syndecans (heparin sulphate proteogly-
cans) leading exclusively to the release of ILVs as exosomes (Baietti
et al., 2012). Furthermore, differential trafficking fates have also been
attributed to the cholesterol levels within MVBs, with ILVs containing
high cholesterol levels preferentially released as exosomes (Möbius
et al., 2003).
The RAB superfamily of small GTPases are also crucial for MVB
trafficking to the plasma membrane, with the ubiquitination status of
RAB7 believed to be essential in determining lysosome or plasma
membrane trafficking (Baietti et al., 2012; Song et al., 2016). RAB27a
and RAB27b are also key mediators of exosome release, regulating MVB
fusion with the plasma membrane (Ostrowski et al., 2010). Other RAB
family members (including RAB11, RAB35 and their effectors) have
also been reported to perform similar roles in cells that do not con-
stitutively express RAB27. A comprehensive review of the role of RABs
in exosome biogenesis may be found here (Blanc and Vidal, 2018).
Once secreted, exosomes can interact with recipient cells through nu-
merous mechanisms, including endocytosis and direct membrane fu-
sion, leading to the intracellular delivery of luminal EV cargoes (Thery
et al., 2009; Mulcahy et al., 2014; van Niel et al., 2018).
Other EV sub-populations of note include microvesicles, which bud
directly from the plasma membrane (Fig. 1). Whilst not as extensively
studied as exosomes, it has been shown that the machinery which
drives the biogenesis of exosomes, including ESCRT proteins and tet-
raspanins, are also crucial for the formation of microvesicles. Due to
this, it is difficult to confidently identify isolated EVs as exosomes
(Gould and Raposo, 2013; Lotvall et al., 2014; Witwer and Théry,
2019). Therefore, we have decided to use the general term extracellular
vesicles (EVs) rather than a specific sub-type of vesicle throughout this
review (Witwer et al., 2013).
3. Changes in extracellular vesicle production and secretion in
senescence
Whilst the enhanced secretome of senescent cells has been ex-
tensively investigated, changes in EV secretion by senescent cells has
only recently received significant research interest (Coppé et al., 2010;
Fig. 1. Biogenesis pathway of Extracellular
Vesicles (EVs).
Microvesicles are formed from outward bud-
ding of the plasma membrane of cells en-
capsulating various cargoes including RNA and
proteins from the cytoplasm. Exosome bio-
genesis pathway: 1. The early endosome re-
peatedly undergoes inward budding forming
intraluminal vesicles (ILVs) using either ESCRT
dependent or independent mechanisms. 2. This
results in a multivesicular body (MVB). 3. The
MVB then fuses with the plasma membrane
and ILVs are released into the extracellular
space where they classified as exosomes. 4.
Alternatively, MVBs fuse with the lysosome
allowing ILVs to be broken down.
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Takasugi, 2018). Lehmann et al. (2008) were the first to investigate the
association between EVs and senescence, demonstrating that irradia-
tion-induced senescence caused an increase in EV production from
human prostate cancer cells (Lehmann et al., 2008). This finding,
supported previous work conducted by Yu and colleagues (2006), who
demonstrated that an increase in EV production from irradiated non–-
small cell lung cancer cells was dependent on the p53 targets tumour
suppressor-activated pathway 6 (TSAP6) and vacuolar protein sorting-
associated protein 32 (VPS32; a key part of the ESCRT complex), al-
though the investigators did not look at senescence specifically (Yu
et al., 2006). Furthermore, Lespagnol et al. (2008) demonstrated a p53-
dependent increase in EV secretion following DNA damage, which was
abrogated in TSAP6-null mice (Lespagnol et al., 2008). Interestingly,
p53 was also implicated in the upregulation of RAB27b (a key com-
ponent of EV secretory pathways) in senescent human SVts8 fibroblasts
(Fujii et al., 2006). Following these early investigations, it has recently
been demonstrated that normal TIG-3 human fibroblasts produce a
greater number of EVs in response to senescence inducing-stimuli in-
cluding replicative senescence, oncogenic RAS expression and the
chemotherapeutic doxorubicin (Takasugi et al., 2017). Subsequent in-
vestigations have demonstrated an increase in EV production in models
of therapy-induced (Kavanagh et al., 2017), H2O2-induced (Terlecki-
Zaniewicz et al., 2018), irradiation-induced (Basisty et al., 2020), on-
cogene-induced (Borghesan et al., 2019), and replicative senescence
(Mensà et al., 2020; Riquelme et al., 2020). Therefore, it appears that,
much like the soluble secretome, EV production increases in multiple
cell types following a variety of different senescence-inducing stimuli.
The mechanisms which underpin the increased production of EVs in
senescence have not been extensively studied. However, recent work by
Choi, Kil and Cho, demonstrated that senescent dermal fibroblasts up-
regulate neutral sphingomyelinase (a key enzyme in ILV biogenesis)
which led to a reduction in EV secretion when inhibited (van Niel et al.,
2018; Choi et al., 2020). Furthermore, the investigators proposed a link
between the dysfunctional lysosomal activity of senescent cells and the
increased rate of EV production, as artificially lowering lysosomal pH in
senescent fibroblasts perturbed EV production, whilst increasing pH in
proliferating fibroblasts increased EV production (Choi et al., 2020).
Together, this research implicates dysfunctional lysosomal activity as a
major factor affecting the rate of EV production by senescent cells.
4. Changes in extracellular vesicle cargo in senescence
EV cargo is derived from the cell of origin, and, as such, can provide
information about the composition of that cell, at the time of EV pro-
duction (Saleem and Abdel-Mageed, 2015; McBride et al., 2017).
However, as described above, EVs are also enriched for a variety of
cargoes, some of which are involved in their biogenesis (van Niel et al.,
2018). Nevertheless, as EVs derive their cargo directly from a producing
cell, changes in cellular content following senescence induction may
alter the composition and luminal cargo of EVs derived from those cells.
The changes in EV composition have now been studied extensively in a
variety of cell types, following a variety of senescence triggers (Kadota
et al., 2018; Takasugi, 2018). These are discussed below in the context
of protein, nucleic acid and lipid constituents.
4.1. Proteins
Soluble proteins have been the most widely investigated factors
within the SASP with constituents including inflammatory cytokines
(e.g. interleukin-1, (IL-1), IL-6), chemokines (e.g. IL-8), growth factors
(e.g. epidermal growth factor (EGF)) and proteases (e.g. matrix me-
talloproteinase-1 (MMP1)) (Coppé et al., 2010). However, recently,
characterisation of EVs and their functional protein cargoes have gar-
nered greater attention and revealed a distinct role as regulatory units
(Takasugi, 2018; Basisty et al., 2020). Takasugi et al, (2017) performed
proteomic analysis of EVs following senescence induction using
doxorubicin (Takasugi et al., 2017). The investigators demonstrated
that EVs isolated from senescent cells promoted the proliferation of
several types of cancer cell, whilst senescent cell derived conditioned
media depleted of EVs attenuated a pro-proliferative effect on MCF-7
breast cancer cells. The tyrosine kinase receptor ephrin receptor A2
(EphA2) was identified as being upregulated in EVs from doxorubicin-
induced senescent cells and established as a key functional cargo for the
pro-proliferative effects of the EVs. Strikingly, this role of EV EphA2
could not be recapitulated using the soluble form of the receptor. This
phenomenon, which suggests that EV derived cargo may be more po-
tent than the soluble form of the same protein, has previously been
reported for the soluble factors interferon gamma (IFN-γ) (Cossetti
et al., 2014) and transforming growth factor beta (TGF-β) (Webber
et al., 2015). This not only emphasises the distinction between EVs and
the soluble SASP but also raises the intriguing possibility that EVs may
play a role in enhancing the signalling of soluble factors.
EVs have also been derived from cancer cells which have undergone
therapy-induced senescence (TIS) (Kavanagh et al., 2017). Investigators
identified changes in key proteins involved in cell proliferation, ATP
depletion, apoptosis and the SASP. It was suggested that EVs may re-
present a route through which TIS cancer cells dispose of these proteins
and thus contribute to cancer cell survival and resistance to che-
motherapy.
One of the key roles of the SASP is the ability to confer paracrine
senescence on neighbouring cells (Acosta et al., 2013). A recent study
by Borghesan et al., demonstrated that EVs derived from oncogenic
RAS-induced fibroblasts can contribute to this effect (Borghesan et al.,
2019). Inhibition of EV production was sufficient to attenuate the
paracrine senescence effect of the SASP. Furthermore, the investigators
demonstrated that EV paracrine senescence was partially mediated
through interferon-induced transmembrane protein 3 (IFTM3). These
findings collectively highlight the potential of EVs as mediators of
cellular communication between senescent cells and the local micro-
environment.
Recently, efforts have been made to fully characterise the secretome
of senescent cells by generating a so called “Atlas” of SASP and EV
factors in different cell types and senescence models (Basisty et al.,
2020). Investigators demonstrated little overlap in protein composition
between these two components of the senescent secretome. Therefore,
from both a functional and compositional perspective, EVs appear to
have a distinct role as regulatory mediators beyond the traditional so-
luble factors which have previously been considered as the main
players within the SASP.
4.2. Nucleic acids
Functional transfer of nuclei acids between cells via EVs was first
demonstrated in 2007 when Valadi et al. demonstrated RNA transfer
from mouse to human mast cells via EVs (Valadi et al., 2007). This
finding led to an increase in research interest surrounding EVs as a
mechanism for cellular communication, with miRNA in senescent cell
derived EVs first being investigated in 2015 (Weiner-Gorzel et al.,
2015). The potential of EVs to deliver nucleic acid cargoes, such as
upregulated miRNAs, from senescent cells, to the cytoplasm of pro-
liferative cells, adds an additional facet to the SASP, as recently de-
monstrated with an assortment of miRNAs triggering senescence in-
duction in previously proliferating cells (Overhoff et al., 2014; Luo
et al., 2015; Xu et al., 2019). miRNAs are the most widely investigated
nucleic acid cargo of EVs and are, therefore, the most extensively dis-
cussed in this review. However, a variety of additional nucleic acids
including DNA, Telomeric repeat-containing RNA (TERRA) and mi-
tochondrial DNA (mtDNA) have been identified in senescent cell de-
rived EVs.
4.2.1. miRNA
Early research investigating the association between senescence,
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EVs and miRNAs demonstrated that senescence induction via over-
expression of miR-433 in A2780 ovarian cancer cells also resulted in the
packaging of miR-433 into EVs. Through this miRNA cargo, the EVs
were implicated as potential contributors to a paracrine senescence
response in recipient cells (Weiner-Gorzel et al., 2015). Recently, in-
vestigations by Fulzele et al., demonstrated that the serum of aged mice
contained EVs with increased levels of miR-34a. Upregulation of miR-
34a was also detected in muscle derived EVs present in the serum of
aged mice and in EVs derived from human myotubes undergoing oxi-
dative stress from H2O2. Furthermore, EVs isolated from H2O2 treated
mouse myoblasts, or mouse myoblasts overexpressing miR-34a, were
found to contain increased levels of miR-34a. The latter two of these EV
populations caused a paracrine senescence effect when cultured with
bone marrow stem cells in vitro, compared to EVs from untreated mouse
myoblasts. Of note, miR-34a has been shown by others to indirectly
regulate p53 through the degradation of the p53 suppressor Sirtuin 1
(SIRT1), which can result in senescence induction (Yamakuchi and
Lowenstein, 2009). Fulzele et al. further demonstrated that EVs could
be detected in multiple tissues, including the fore- and hind-limb, fol-
lowing tail-vein injection of EVs derived from miR-34a overexpressing
mouse myoblasts into healthy mice. Additionally, bone marrow cells
isolated from the limbs of untreated mice were cultured ex vivo with
either EVs from mouse myoblasts overexpressing miR-34a or EVs iso-
lated from control cells. Finally, the authors determined that treatment
with EVs from mouse myoblasts overexpressing miR-34a resulted in a
reduction in SIRT1 at both the mRNA and protein level in bone marrow
cells, although the functional consequences of this reduction were not
explored (Fulzele et al., 2019). In combination with SIRT1, DNA me-
thyltransferase 1 (DNMT1) acts to ensure genomic integrity and exert
pro-longevity effects. Mensa et. al., explored this by screening replica-
tively senescent human umbilical vein endothelial cells (HUVECs) and
their small EVs for miRNAs that target SIRT1 and/ or DNMT1. Several
miRNAs were identified including miR-21-5p and miR-217, which the
authors demonstrated were upregulated in replicatively senescent
human aortic endothelial cells (HAECs) and their EVs. This was also
observed in a model of drug-induced senescence established in both
HUVECs and HAECs. Senescent EVs were able to transfer miR-21-5p
and miR-217 to recipient cells, which resulted in reduced expression of
both SIRT1 and DNMT1, leading to a decrease in cell proliferation and
an increase in senescent cell markers, including p16, IL-6 and IL-8
mRNA (Mensà et al., 2020). Therefore, EV derived miRNA cargo from
aged cells may constitute a potential “dark” pathological role of EVs by
facilitating the propagation of senescence between tissues, raising the
possibility that similar interactions could be driven by a diverse set of
miRNAs and cell types in a context dependent manner.
Wound healing has often been reported as one of the “bright”
beneficial effects of the SASP (Demaria et al., 2014) and, interestingly,
senescent human dermal fibroblast derived EVs containing miR-23a-3p
have been shown to play a role in wound healing through the transfer of
this miRNA to non-senescent keratinocytes, resulting in more efficient
wound healing (Terlecki-Zaniewicz et al., 2019). The miRNA profile of
EVs derived from H2O2-induced senescent human fibroblasts was al-
tered when compared to EVs from quiescent fibroblasts and, intrigu-
ingly, developed with time after senescence induction. Furthermore,
the authors identified miRNAs that are specifically packaged into EVs
for secretion from the senescent cell, including miR-15b-5p and miR-
29c-3p, and miRNAs that are specifically retained by senescent cells,
such as miR-409-5p and miR-323a-3p. The top 20 most secreted
miRNAs were predicted to target transcription factors that are known
pro-apoptotic mediators, suggesting a role for EV-packaged miRNAs as
anti-apoptotic members of the SASP. The authors confirmed this po-
tential role by demonstrating that EVs from H2O2-induced senescent
human fibroblasts reduced apoptosis in recipient fibroblast cells un-
dergoing acute stress from high H2O2 levels, compared to EVs from
quiescent control fibroblasts (Terlecki-Zaniewicz et al., 2018). There-
fore, EV carried miRNAs represent underappreciated yet important
players within both the “bright” and “dark” sides of the SASP.
4.2.2. Telomeric repeat-containing RNA (TERRA) and telomeric DNA
Telomere shortening – a key facet of replicative senescence – in-
creases the expression of Telomeric repeat-containing RNA (TERRA)
within the cell cytoplasm (Cusanelli et al., 2013; Takasugi, 2018);
TERRA has been identified in EVs and has been demonstrated to induce
inflammatory gene expression in recipient cells (Wang et al., 2015b;
Wang and Lieberman, 2016). However, a link to increased TERRA in
senescent EVs has not yet been established. Contrasting the effects of
TERRA, cytoplasmic telomeric DNA has been shown to have an anti-
inflammatory role, as reviewed previously (Bonafè et al., 2020). The
authors speculate that telomeric DNA fragments could be packaged into
EVs and exert anti-inflammatory benefits on recipient cells in order to
delay age related pathologies.
4.2.3. DNA
The presence of cytoplasmic chromatin DNA fragments (CCFs)
within senescent cells has been recently established (Adams et al.,
2013), with CCFs potentially acting as indirect regulators of the SASP
through the cGAS-STING pathway. In brief, cGAS directly binds CCFs
and subsequently synthesises cyclic GMP-AMP (cGAMP), which in turn
activates the endoplasmic reticulum adaptor STING, leading to activa-
tion of crucial SASP transcription factors including NF-κB. (Dou et al.,
2017; Glück et al., 2017). Chromosomal DNA secretion from cells
within EVs has been demonstrated to increase with senescence, and
appears to maintain cellular homeostasis by removing potentially
harmful aberrant DNA, thus avoiding a ROS dependent DNA damage
response (Takasugi et al., 2017). This principle was validated by the
inhibition of EV section through both siRNA knockdown of ALIX or
RAB27a, or through use of the EV secretion inhibitor GW4869, which
led to an increased expression of the DNA damage marker γ-H2AX and
phosphorylation of key DNA damage response kinases – ATM and ATR
(Takahashi et al., 2017; Takasugi et al., 2017). Inhibition of CCFs ex-
cretion in EVs also resulted in cells becoming prone to apoptosis. This
pathway implicates EV secretion as a homeostatic mechanism, re-
turning to the concept of “waste disposal” first suggested decades ear-
lier (Johnstone, 1992). Interestingly, CCF containing vesicles could
elicit a DNA damage response in recipient TIG-3 fibroblasts suggesting
that, whilst this mechanism may be beneficial to the producing cell, it
may have detrimental consequences in the surrounding microenviron-
ment (Takahashi et al., 2017). This is reminiscent of the SASP as a
whole and suggests that senescent cell derived EVs and their cargo may
contribute to both sides of the bright and dark dichotomy of the SASP.
4.2.4. Mitochondrial DNA (mtDNA)
Along with cellular senescence, mitochondrial dysfunction has been
proposed as one of nine key “pillars” of ageing (López-Otín et al., 2013).
Oxidative stress is a key trigger of senescence and excessive reactive
oxygen species (ROS) production has been implicated in the protein
damage considered to be a hallmark of senescence and ageing (Kaushik
and Cuervo, 2015; Höhn et al., 2017). Accumulation of aberrant cel-
lular products due to mitochondrial dysfunction underpins the “garbage
catastrophe” theory of ageing, whereby the production of cellular waste
products outstrips disposal or recycling mechanisms, thus leading to
impairment of homeostasis (Terman et al., 2010; Baixauli et al., 2014;
Picca et al., 2019). As discussed above, EVs have long been considered a
potential route for cellular waste disposal and it has been proposed that
EVs may serve as a reserve mechanism to meet demand where excessive
waste production overcomes lysosomal capacity, particularly during
oxidative stress (Soubannier et al., 2012; Picca et al., 2019). This is
supported by the observable increase in EV secretion following H2O2
induced senescence (Terlecki-Zaniewicz et al., 2018). Furthermore,
mitochondrial DNA (mtDNA) has been identified in EVs isolated from
astrocytes (Guescini and Genedani, 2010) and myoblasts (Guescini and
Guidolin, 2010) suggesting that mitochondrial components may be
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removed via a vesicular route. Supporting this concept is evidence that
oxidative stress can cause astrocytes (Hayakawa et al., 2016) and me-
senchymal stem cells (Phinney et al., 2015) to release EVs containing
mitochondrial particles (Picca et al., 2019). Therefore, the reprogram-
ming of cellular metabolism in response to oxidative stress-induced
senescence may involve the use of EVs to dispose of aberrant mi-
tochondrial components. Parallels to this may be drawn in therapy
resistant metastatic breast cancer cells which were demonstrated to
contain a complete mitochondrial genome (Soubannier et al., 2012).
Furthermore, these cells were able to produce EVs containing mtDNA in
response to oxidative stress, contributing to therapeutic resistance
(Soubannier et al., 2012). The consequences of these EVs to cells in the
surrounding microenvironment is not known and is worthy of further
investigation. Overall, EVs represent an underexplored dimension to
the metabolic reprogramming which occurs following senescence in-
duction.
4.3. Lipids
A relatively underexplored facet of senescent cell derived EVs is
their lipid profile. Several recent publications have identified changes
in the lipid profiles of oncogene-induced senescent fibroblast derived
EVs. Enrichment was demonstrated in hydroxylated sphingomyelin,
lyso- and ether-linked phospholipids, when compared to the producing
cell, indicating that the lipid composition of EVs may differ from the
parental cells more than previously appreciated (Buratta et al., 2017).
Furthermore, a subsequent study identified that EVs from oncogene-
induced senescent fibroblasts showed increased levels of mono-
unsaturated and decreased level of saturated fatty acids, as compared to
control cells (Sagini et al., 2018). Intriguingly, EVs from bone-derived
mesenchymal stem cells have been demonstrated to contribute to
paracrine senescence when loaded with very long chain C24:1 ceramide
(Khayrullin et al., 2019). The lipid composition of senescent cell de-
rived EVs, therefore, potentially represents an underexplored me-
chanism through which senescent cells contribute to the paracrine ef-
fects of the SASP.
5. Role of extracellular vesicles in ageing
5.1. Changes in EV production with aging
Senescent cells have previously been demonstrated to accumulate
with age and at sites of age-related diseases (Nielsen et al., 1999;
Krishnamurthy et al., 2004, 2006). Given that, as described above, se-
nescent cells have an increased rate of EV secretion, it might be pre-
dicted that EV production would increase with ageing. However, con-
tradictory data has emerged regarding the change in EV production
with age. An initial study concluded that, although the soluble SASP
component IL-6 increased in aged volunteers, EV concentration did not
alter (Alberro et al., 2016). Another suggested that fewer EVs could be
isolated from the plasma samples of elderly patients. However, the
authors also noted that circulating EVs were increased in individuals
that smoked or had higher a body mass index (BMI), both of which are
correlated with higher levels of senescent cells in tissues (Nyunoya
et al., 2006; Eitan et al., 2017). By contrast, circulating EVs have also
been demonstrated to increase in aged subjects (Im et al., 2018) and in
mouse models of normal ageing (Alibhai et al., 2020; Qureshi et al.,
2020). Aged chondrocytes isolated from arthritic cartilage have also
been shown to produce an increased number of EVs. (Jeon et al., 2019).
One possible explanation for these conflicting data is a reported in-
crease in clearance of EVs in ageing, which may mask increased pro-
duction in certain settings (Eitan et al., 2017). Another consideration, is
the use of different methods of EV characterisation, with one study
demonstrating that whilst the number of circulating particles detected
by nanoparticle tracking analysis (NTA) was higher in young (3 month)
mice, EV markers were enriched in old (18–21 month) mice as
determined by western blot (Alibhai et al., 2020). This demonstrates
the importance of utilising multiple analysis approaches when char-
acterising EVs (Lötvall et al., 2014). Further complexity also comes
from the suggestion that EV concentration increases with certain age-
related diseases (Tan et al., 2017). Finally, EV concentration could be
affected by confounding factors including medication used in the
treatment of age-related pathologies, as it has been shown that the
regular use of aspirin in elderly patients reduced the number of platelet
derived EVs without altering the overall number of circulating EVs
(Goetzl et al., 2016).
5.2. Changes in EV cargo with age
Whilst the level of EV production in age remains an open question, it
is clear from numerous studies that EV composition changes with age.
miR-31 has been demonstrated to increase and Galectin-3 determined
to decrease, in EVs isolated from elderly patients. These changes re-
sulted in both the impairment of osteogenic differentiation of me-
senchymal stem cells (MSCs) and compromised tissue regeneration
(Weilner and Keider, 2016; Weilner and Schraml, 2016). Furthermore,
EVs from the bone marrow of aged mice have also been demonstrated
to reduce osteogenic differentiation, in this case through increased miR-
183-5p expression, leading to a reduction in bone mineral density and
bone function (Davis et al., 2017). The mitochondrial content of im-
mune cell derived EVs was also recently shown to decline with age
(Picca et al., 2019; Zhang et al., 2020). Macrophage-derived serum EVs
from aged (> 65 years) individuals were also shown to contain sig-
nificantly higher levels of IL-6 and IL-12 mRNA than matched EVs from
young (21–45 years) volunteers (Mitsuhashi et al., 2013). The miRNA
cargo of EVs has also been implicated as a potential biomarker of pa-
thological aging. Ipson et al., identified 8 miRNAs that are increased in
EVs from frail older individuals compared to both robust older and
young patients (Ipson et al., 2018). Furthermore, expression of miR-21
has been previously recognised to increase in pathological ageing
(Olivieri et al., 2012) and was recently demonstrated to be one of
several miRNAs that were upregulated in EVs in both aged mice and an
irradiation induced global model of senescence (Alibhai et al., 2020).
miR-21-5p has also recently been proposed as a potential marker of
senescence and inflammageing (Mensà et al., 2020).
Changes in EV cargoes have also been described in pathologies as-
sociated with age. EVs from senescent coronary artery endothelial cells
and from patients with acute coronary artery syndrome-induced pre-
mature endothelial dysfunction have been demonstrated to propagate a
paracrine senescence phenotype (Abbas et al., 2017). Aortic smooth
muscle cell calcification may also be facilitated by EVs from senescent
endothelial cells, and from the plasma of elderly patients, representing
another pathology closely linked to age (Alique et al., 2018). EVs iso-
lated from senescent chondrocytes from patients with osteoarthritis
(OA) were also able to induce a paracrine senescence effect in pro-
liferative chondrocytes and inhibited cartilage formation, indicating a
role in disease severity (Jeon et al., 2019). Senolytic clearance of se-
nescent cells reduced EV production in OA patients and also altered
miRNA cargo composition. Senolytic treatment in aged mice induced
primarily immunological changes in EV proteins, and age-related sy-
novial EVs were demonstrated to transfer arthritic disease to young
animals, demonstrating a pathological role in OA (Jeon et al., 2019).
EVs have also been implicated in the distribution of damaged proteins
in neurodegenerative conditions including Alzheimer’s, Huntington’s
and Parkinson’s disease (Soria et al., 2017; D’Anca et al., 2019). Fur-
thermore, EV encapsulated miR-21-5p was also found to be upregulated
in a range of patients with age-related diseases compared to healthy
individuals of the same age or healthy young individuals (Olivieri et al.,
2017). Therefore, changes in EV composition have been identified
throughout both age and age-related diseases (Urbanelli et al., 2016;
Kadota et al., 2018).
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5.3. Use of EVs as theraputics in age-related pathologies
EVs are emerging as attractive novel therapeutic agents in a variety
of settings and have, to date, proceeded as far as phase II clinical trials
(Besse et al., 2016). Strikingly, extracellular nicotinamide phosphor-
ibosyl transferase (eNAMPT) containing EVs were recently demon-
strated to extend the health-span and increase the physical activity of
elderly mice (Yoshida et al., 2019). A variety of different other ther-
apeutic approaches have also been proposed, including the replacement
of cell-based therapies with EV treatments and the use of EVs as drug
delivery vectors (Ha et al., 2016; Boulestreau et al., 2020). Of particular
interest is the use of EVs as a means of RNA interference technology,
through loading with a miRNA or siRNA “payload” which could then be
delivered to a recipient cell (Hagiwara et al., 2014). EVs present sig-
nificant advantages over other more established delivery systems, such
as liposomes, due to a low toxicity, presence of membrane proteins and
a lack of immunogenic effects (Lener et al., 2015; Ohno et al., 2016).
Furthermore, efforts have been made to develop EVs which are speci-
fically targeted to cells or tissues through the display of antibody
fragments or functional peptides (Ohno et al., 2013; Longatti et al.,
2018; Tian et al., 2018). This has the potential to maximise efficacy
whilst limiting off-target effects (Ha et al., 2016). Here, we discuss the
use of EV based theraeptuics in ageing.
The loss of tissue regeneration represents a universal characteristic
of ageing (Gorgoulis et al., 2019). This is driven by a process of stem
cell exhaustion which has been proposed (along with senescence) as
one of the hallmarks of ageing (López-Otín et al., 2013). Stem cell based
therapies have an established regenerative potential within the tissue
microenvironment but are limited by adverse effects such as tumour
formation (Ma et al., 2020). Harnessing the secretome of stem cells has
been proposed as an alternative therapeutic approach which may
overcome this shortcoming and utilising stem cell derived EVs (SC-EVs)
has become the subject of significant research interest (Boulestreau
et al., 2020). SC-EVs have shown promising results in a number of
settings, including the regeneration of liver tissue from a fibrotic state
in mice (Li et al., 2013; Hyun et al., 2015), improvement of functional
recovery after stroke in rats (Xin et al., 2013), restriction of pulmonary
hypertension under hypoxic conditions in mice (Lee et al., 2012),
protection of cardiomyocytes from apoptosis in ischemic myocardium
(Wang et al., 2015a) and acceleration of cutaneous wound healing
(Golchin et al., 2018; Chen et al., 2019). SC-EVs have also been mod-
ified with functional peptides to target EVs to specific tissues, of par-
ticular note is the use of rabies viral glycoprotein (RVG) tagged SC-EVs
to target the central nervous system, for the functional improvement of
Fig. 2. The Bright and Dark Side of Extracellular Vesicles in Senescence and Ageing.
The senescence associated secretory phenotype (SASP) has been demonstrated to have beneficial (Bright, yellow) and detrimental (Dark, grey) roles within both
normal homeostatic processes and pathology. These diverse and varied effects are driven by heterogeneity in the composition of the SASP, which is influenced by
factors including cell type, senescence trigger and disease state. The SASP is also a variable phenotype, developing over the course of senescence induction, leading to
significant alterations in constituent factors. Extracellular vesicles (EVs, pink) have recently emerged as key mediators within the SASP and have also been de-
monstrated to have a wide range of roles in senescence and ageing. As with the more traditional “soluble” SASP, this vesicular secretome also mediates a hetero-
geneous set of effects that may be considered “bright” or “dark” depending on the specific cellular context. This is driven by a diverse set of EV cargos including
proteins, nucleic acids and lipids, which underpin the functional roles of EVs within senescence and ageing. However, as emerging players within the SASP, further
work is required to elucidate the contribution of EVs to both the homeostatic and pathological effects of senescent cells. In particular, advancements in isolation and
characterisation methodologies will likely lead to the establishment of further heterogeneity in EV sub-populations, adding further complexity to the role of these
vesicles within the secretome of senescent cells. EphA2 (Ephrin-A2), C24:1 ceramide (Long chain C24:1 ceramide), IFITM3 (Interferon-induced transmembrane
protein 3), TERRA (Telomeric repeat-containing RNA), CCFs (Cytoplasmic chromatin fragments), miRNAs (microRNAs), mtDNA (Mitochondrial DNA) eNAMPT
(extracellular nicotinamide phosphoribosyl transferase) Figure created with BioRender. (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article).
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mice in a model of Alzheimer’s disease (Cui et al., 2019). In other
studies, RVG tagged EVs have demonstrated the functional delivery of
siRNAs to the brain in several models of neurodegenerative disease,
thus highlighting the potential of EVs as nucleic acid delivery vectors
(Alvarez-Erviti et al., 2011; Cooper et al., 2014). Following these pro-
mising preclinical models the International Society for Extracellular
Vesicles (ISEV) have released a positional paper for consideration as EV
based therapies move into clinical trials (Lener et al., 2015).
Finally, whilst not a true EV based approach, Muñoz-Espín et al.,
have developed a synthetic nanoparticle based technology which mir-
rors many of the advantages of EV based therapeutics (Muñoz-Espín
et al., 2018). Here, 100 nm silica beads are coated with a layer of ga-
lacto-oligosaccharides (GalNP) and upon uptake by recipient cells,
these beads are trafficked to the lysosome and subsequently released by
exocytosis. However, in senescent cells, high levels of lysosomal β-ga-
lactosidase activity digest the GalNP coating leading to a release of any
luminal cargo. Investigators used these beads to selectively clear se-
nescent cells through use of chemotherapeutic cargos in vivo whilst also
reducing the toxicities typically associated with those agents (Muñoz-
Espín et al., 2018). Together, these studies highlight the exciting po-
tential of both biological and synthetic nanoparticle based therapeutics
in ageing.
6. Conclusion
The SASP is a key hallmark of senescence with both beneficial and
deleterious effects in homeostasis and pathology. These numerous and
varied roles have thus far predominantly focused on the soluble factors
produced including cytokines, chemokines, growth factors and tissue
remodelling agents (Coppe et al., 2008; Coppé et al., 2010). However,
more recent studies have begun to highlight the role of extracellular
vesicles within the SASP (Takasugi, 2018). EVs represent a mechanism
through which a wide range of different cargoes may engage in inter-
cellular signalling and, in particular, brings the possibility of the
functional transfer of nucleic acids between senescent cells and their
microenvironment (Terlecki-Zaniewicz et al., 2018; Jeon et al., 2019).
As with the soluble SASP, the role of EVs in senescence and ageing
appears to have both beneficial and detrimental effects depending on
the cellular context. These are outlined in Fig. 2. However, despite these
recent advances, the senescence field must now reflect on the im-
portance of research methodology when investigating EVs, an issue
which has recently become the subject of focus from the International
Society for Extracellular Vesicles (ISEV) (Lötvall et al., 2014; Théry
et al., 2018). In particular, care needs to be employed in separating the
soluble and vesicular fractions of the SASP, given the propensity for co-
isolation of soluble proteins with EVs when employing the widely used
ultracentrifugation method of isolation (Foers et al., 2018). Therefore,
in order to confidently attribute effects to EVs derived from senescent
cells, efforts must be made to maximise isolation rigor and stringency.
Nevertheless, EV production and composition have been extensively
demonstrated to change in multiple models of senescence. Whilst more
work is required to fully elucidate their role in age and age-related
pathologies, EVs represent an alternate method for senescent cells to
modulate their local micro-environment beyond the traditional, soluble
SASP.
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